Article

PTEN Knockout Prostate Cancer as a Model for Experimental Immunotherapy

Department of Medicine, University of California-Los Angeles, California, USA.
The Journal of urology (Impact Factor: 4.47). 12/2008; 181(1):354-62. DOI: 10.1016/j.juro.2008.08.124
Source: PubMed

ABSTRACT

Testing immunotherapeutic strategies for prostate cancer has been impeded by the lack of relevant tumor models in immunocompetent animals. This opportunity is now provided by the recent development of prostate specific PTEN knockout mice, which show spontaneous development of true adenocarcinoma arising from prostate epithelium and more faithfully recapitulate the human disease than any previous model. We investigated the feasibility of using tumor cells derived from this model to test tumor vaccination and adoptive immunotherapeutic strategies for prostate cancer.
PTEN-CaP8 adenocarcinoma cells derived from the biallelic PTEN knockout prostate cancer model were used to vaccinate nontumor bearing litter mates. Tumor specific effector cells were generated from splenocytes of vaccinated mice by mixed lymphocyte-tumor reactions, and antiproliferative effects and cytokine generation were examined in vitro. The effect of vaccination or adoptive immunotherapy on luciferase marked PTEN-CaP8 subcutaneous tumors was monitored by tumor volumetric measurements and noninvasive bioluminescence imaging.
Vaccination of litter mate mice with irradiated PTEN-CaP8 cells showed a significant prophylactic effect against the subsequent tumor challenge. Effector cells harvested from vaccinated litter mates showed significant interferon-gamma secretion upon co-incubation with PTEN-CaP8 target cells and they were capable of efficient target cell growth inhibition in vitro. Intratumor adoptive transfer of effector cells resulted in significant growth inhibition of preestablished prostate tumors in vivo.
The PTEN knockout model serves as a highly useful model in which to investigate tumor cell vaccination and adoptive immunotherapeutic strategies in the context of true adenocarcinoma of the prostate. This model should accelerate efforts to develop effective immunotherapies for human prostate cancer.

Download full-text

Full-text

Available from: Takahiro Kimura
  • Source

    Full-text · Thesis · Aug 2009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Mice provide us with an excellent preclinical model of human prostate cancer. They have expanded our understanding of the molecular pathways involved in prostate carcinogenesis as well as allowing us to explore both novel and traditional treatment regimes based on the molecular profile of these lesions. Continuing refinement of the transgenic prostate models has proven challenging since no one model seems to represent the entire continuum of the disease, thus currently limiting its applicability to the human condition. This platform may potentially have major impact in validation of drug targeting specific biological process of prostate carcinogenesis, supplementing (or even replacing) many of the current in vitro and in vivo assays with the in vivo environment that transgenic prostate models provide. Objective/method: This review focuses primarily on the current state of murine model systems as a preclinical therapeutic platform for the treatment of prostate cancer, as well as hope for the future of the field. Conclusion: Much of the work in the drug discovery field has been done with the PTEN(-/-) and TRAMP models of prostate cancer. Despite their limitations they have contributed much to our understanding of the pathophysiology of the disease. There is, however, a need for transgenic models that better reflect the stepwise progression found in the human condition. We feel that they will prove to be invaluable as a preclinical platform regarding efficacy and tolerability of various anticancer agents, which ultimately allows us to translate these findings to the clinical setting to prognosticate and ultimately render cancer patients disease-free.
    No preview · Article · Aug 2009 · Expert Opinion on Drug Discovery
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer remains a leading cause of morbidity and mortality. Despite advances in understanding, detection, and treatment, it accounts for almost one-fourth of all deaths per year in Western countries. Prostate cancer is currently the most commonly diagnosed noncutaneous cancer in men in Europe and the United States, accounting for 15% of all cancers in men. As life expectancy of individuals increases, it is expected that there will also be an increase in the incidence and mortality of prostate cancer. Prostate cancer may be inoperable at initial presentation, unresponsive to chemotherapy and radiotherapy, or recur following appropriate treatment. At the time of presentation, patients may already have metastases in their tissues. Preventing tumor recurrence requires systemic therapy; however, current modalities are limited by toxicity or lack of efficacy. For patients with such metastatic cancers, the development of alternative therapies is essential. Gene therapy is a realistic prospect for the treatment of prostate and other cancers, and involves the delivery of genetic information to the patient to facilitate the production of therapeutic proteins. Therapeutics can act directly (eg, by inducing tumor cells to produce cytotoxic agents) or indirectly by upregulating the immune system to efficiently target tumor cells or by destroying the tumor's vasculature. However, technological difficulties must be addressed before an efficient and safe gene medicine is achieved (primarily by developing a means of delivering genes to the target cells or tissue safely and efficiently). A wealth of research has been carried out over the past 20 years, involving various strategies for the treatment of prostate cancer at preclinical and clinical trial levels. The therapeutic efficacy observed with many of these approaches in patients indicates that these treatment modalities will serve as an important component of urological malignancy treatment in the clinic, either in isolation or in combination with current approaches.
    No preview · Article · May 2010 · Postgraduate Medicine
Show more